Clarification on the news article by internet media on Jun 21,2019
2019.Jun.21
Company Chairman Mr. Michael Chang and other five executives received an acquittal for insider trading case by Taiwan Shilin District Court
2019.Jun.17
Clarification on new article by Economy Daily News dated Jun 16, 2019
2019.Jun.15
OBI-888 completes Phase I safety evaluation and demonstrates its safety and tolerability with no major concerns
2019.Jun.14
Announcement of the company's cash capital increase and base date
2019.Jun.10
Board of directors of the company waived subscription rights exceeding half of the total subscribable shares. Shares to be subscribed by designated persons
2019.May.06
Letter received from National Medical Products Administration (NMPA) of China regarding Adagloxad Simolenin (OBI-822) Phase III clinical study to be resubmitted after supplementation
2019.Apr.22
Supplementary announcement for the company to issue ordinary shares through rights offering
2019.Apr.19
Supplementary announcement for 2019 Annual General Meeting
2019.Apr.18
Announcement for the company to issue ordinary shares through rights offering and bank designated for collection and deposition
